A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs (vol 11, pg 323, 2015)

被引:2
|
作者
O'Hagan, Steve [1 ,2 ]
Swainston, Neil [2 ,3 ]
Handl, Julia [4 ]
Kell, Douglas B. [1 ,2 ]
机构
[1] Univ Manchester, Sch Chem, Manchester M1 7DN, Lancs, England
[2] Univ Manchester, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England
[3] Univ Manchester, Sch Comp Sci, Manchester M1 7DN, Lancs, England
[4] Univ Manchester, Manchester Business Sch, Manchester M1 7DN, Lancs, England
基金
英国生物技术与生命科学研究理事会;
关键词
Genome-wide metabolic reconstruction; Recon 2; Cheminformatics; KNIME; Metabolite-likeness; Drug-likeness;
D O I
10.1007/s11306-014-0745-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We exploit the recent availability of a community reconstruction of the human metabolic network ('Recon2') to study how close in structural terms are marketed drugs to the nearest known metabolite(s) that Recon2 contains. While other encodings using different kinds of chemical fingerprints give greater differences, we find using the 166 Public MDL Molecular Access (MACCS) keys that 90 % of marketed drugs have a Tanimoto similarity of more than 0.5 to the (structurally) 'nearest' human metabolite. This suggests a 'rule of 0.5' mnemonic for assessing the metabolite-like properties that characterise successful, marketed drugs. Multiobjective clustering leads to a similar conclusion, while artificial (synthetic) structures are seen to be less human-metabolite-like. This 'rule of 0.5' may have considerable predictive value in chemical biology and drug discovery, and may represent a powerful filter for decision making processes.
引用
收藏
页码:340 / 340
页数:1
相关论文
共 6 条
  • [1] A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs
    Steve O′Hagan
    Neil Swainston
    Julia Handl
    Douglas B. Kell
    Metabolomics, 2015, 11 : 323 - 339
  • [2] Synthetic Approaches to the New Drugs Approved During 2015 (vol 60, pg 6480, 2017)
    Flick, Andrew C.
    Ding, Hong X.
    Leverett, Carolyn A.
    Kyne, Robert E., Jr.
    Liu, Kevin K-C.
    Fink, Sarah J.
    O'Donnell, Christopher J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (20) : 8680 - 8680
  • [3] New anthyarrhythmic drugs for atrial fibrillation (vol 11, pg 705, 2015)
    Matassini, Maria Vittoria
    Guerra, Federico
    Scappini, Lorena
    Urbinati, Alessia
    Capucci, Alessandro
    FUTURE CARDIOLOGY, 2016, 12 (01) : 102 - 102
  • [5] Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria (vol 58, pg 3626, 2015)
    Klingler, Franca-M.
    Wichelhaus, Thomas A.
    Frank, Denia
    Cuesta-Bernal, Jenifer
    El-Delik, Jasmin
    Mueller, H. Florian
    Sjuts, Hanno
    Goettig, Stephan
    Koenigs, Arno
    Pos, Klaas M.
    Pogoryelov, Denys
    Proschak, Ewgenij
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (15) : 6320 - 6320
  • [6] Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs (vol 43, pg 1691, 2015)
    Mordente, A.
    Silvestrini, A.
    Martorana, G. E.
    Tavian, D.
    Meucci, E.
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (06) : 689 - 689